Department of Chemistry, Saint Louis University, Saint Louis, Missouri 63103, United States.
Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont 05401, United States.
J Med Chem. 2023 Jun 22;66(12):7834-7848. doi: 10.1021/acs.jmedchem.3c00110. Epub 2023 Jun 2.
Our previous work identified compound (SLU-2633) as a potent lead compound toward the identification of a novel treatment for cryptosporidiosis, caused by the parasite (EC = 0.17 μM). While this compound is potent and orally efficacious, the mechanism of action and biological target(s) of this series are currently unknown. In this study, we synthesized 70 compounds to develop phenotypic structure-activity relationships around the aryl "tail" group. In this process, we found that 2-substituted compounds are inactive, confirmed that electron withdrawing groups are preferred over electron donating groups, and that fluorine plays a remarkable role in the potency of these compounds. The most potent compound resulting from this work is SLU-10482 (, EC = 0.07 μΜ), which was found to be orally efficacious with an ED < 5 mg/kg BID in a -infection mouse model, superior to SLU-2633.
我们之前的工作确定了化合物 (SLU-2633) 是一种潜在的先导化合物,可用于鉴定一种新的隐孢子虫病治疗方法,这种寄生虫引起的隐孢子虫病(EC = 0.17 μM)。虽然这种化合物具有很强的效力和口服疗效,但该系列的作用机制和生物靶标目前尚不清楚。在这项研究中,我们合成了 70 种化合物,以开发围绕芳基“尾巴”基团的表型结构-活性关系。在这个过程中,我们发现 2-取代的化合物没有活性,证实了吸电子基团优于供电子基团,并且氟在这些化合物的效力中起着显著的作用。这项工作得到的最有效化合物是 SLU-10482(, EC = 0.07 μΜ),在 -感染小鼠模型中发现其具有口服疗效,ED < 5 mg/kg BID,优于 SLU-2633。